tradingkey.logo
๎™

MannKind Corp

MNKD
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

3.750USD

-0.030-0.79%
์ข…๊ฐ€ย 08/01, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
1.14B์‹œ๊ฐ€์ด์•ก
37.84P/E TTM
๎™
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-0.79%

5์ผ

-7.64%

1๊ฐœ์›”

+4.17%

6๊ฐœ์›”

-32.68%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

-41.68%

1๋…„

-29.78%

์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

๊ธฐ๊ด€ ๋“ฑ๊ธ‰๎˜ฐ๎˜ฐ

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

8 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
BUY
ํ˜„์žฌ ๋“ฑ๊ธ‰
9.125
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
143.33%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

552
์ด๊ณ„
5
์ค‘๊ฐ„
6
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
MannKind Corp
MNKD
8
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
27
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111

์ง€ํ‘œ

๎˜ฐ
๎˜ฐ

์ง€ํ‘œ ๊ธฐ๋Šฅ์€ ๋‹ค์–‘ํ•œ ๊ธฐ๋ฒ• ์ง€ํ‘œ๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ ์—ฌ๋Ÿฌ ์ข…๋ชฉ์— ๋Œ€ํ•œ ๊ฐ€์น˜์™€ ๋ฐฉํ–ฅ ๋ถ„์„์„ ์ œ๊ณตํ•˜๋ฉฐ, ๊ธฐ์ˆ ์  ์š”์•ฝ๋„ ํ•จ๊ป˜ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.

์ด ๊ธฐ๋Šฅ์—๋Š” ์ผ๋ฐ˜์ ์œผ๋กœ ์‚ฌ์šฉ๋˜๋Š” 9๊ฐ€์ง€ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๊ฐ€ ํฌํ•จ๋ฉ๋‹ˆ๋‹ค: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX, MA. ๋˜ํ•œ ํ•„์š”์— ๋”ฐ๋ผ ์‹œ๊ฐ„ ํ”„๋ ˆ์ž„์„ ์กฐ์ •ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ธฐ์ˆ  ๋ถ„์„์€ ํˆฌ์ž ์ฐธ์กฐ์˜ ์ผ๋ถ€์ผ ๋ฟ์ด๋ฉฐ, ๋ฐฉํ–ฅ์„ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•ด ์ˆซ์ž ๊ฐ’์„ ์‚ฌ์šฉํ•˜๋Š” ๋ฐ์—๋Š” ์ ˆ๋Œ€์ ์ธ ๊ธฐ์ค€์ด ์—†์Šต๋‹ˆ๋‹ค. ๊ฒฐ๊ณผ๋Š” ์ฐธ์กฐ์šฉ์ผ ๋ฟ์ด๋ฉฐ, ์ง€ํ‘œ ๊ณ„์‚ฐ ๋ฐ ์š”์•ฝ์˜ ์ •ํ™•์„ฑ์— ๋Œ€ํ•ด์„œ๋Š” ์ฑ…์ž„์ง€์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

1๋ถ„
15๋ถ„
30๋ถ„
1์‹œ๊ฐ„
์ผ๊ฐ„
์ฃผ๊ฐ„
์›”๊ฐ„
1๋ถ„
15๋ถ„
30๋ถ„
์ผ๊ฐ„๎˜ฎ
๋งค๋„
๋งค๋„(10)
์ค‘๋ฆฝ(1)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๋งค๋„(4)
์ค‘๋ฆฝ(1)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-0.009
๋งค๋„
RSI(14)
43.850
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
18.349
๋งค๋„
ATR(14)
0.158
์ €๋ณ€๋™์„ฑ
CCI(14)
-138.771
๋งค๋„
Williams %R
88.372
๊ณผ๋งค์ˆ˜
TRIX(12,20)
0.085
๋งค๋„
StochRSI(14)
0.000
๊ณผ๋งค์ˆ˜
์ด๋™ ํ‰๊ท 
๋งค๋„(6)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
3.836
๋งค๋„
MA10
3.917
๋งค๋„
MA20
3.861
๋งค๋„
MA50
3.931
๋งค๋„
MA100
4.388
๋งค๋„
MA200
5.344
๋งค๋„

๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๋ฐ์ดํ„ฐ ์—†์Œ

์ด ์ˆ˜์ต

๋ฐ์ดํ„ฐ ์—†์Œ

ํšŒ์‚ฌ๎˜

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
์ข…๋ชฉ ์ฝ”๋“œ MNKD
ํšŒ์‚ฌMannKind Corp
CEODr. Michael E. Castagna, Pharm.D.
์›น์‚ฌ์ดํŠธhttps://mannkindcorp.com/
tradingkey.logo
tradingkey.logo
๋‹น์ผ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” Refinitiv์—์„œ ์ œ๊ณตํ•˜๋ฉฐ, ์ด์šฉ ์•ฝ๊ด€์ด ์ ์šฉ๋ฉ๋‹ˆ๋‹ค. ์—ญ์‚ฌ์  ๋ฐ ํ˜„์žฌ ์ข…๊ฐ€ ๋ฐ์ดํ„ฐ๋Š” Refinitiv์—์„œ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ชจ๋“  ์‹œ์„ธ๋Š” ํ˜„์ง€ ๊ฑฐ๋ž˜์†Œ ์‹œ๊ฐ„ ๊ธฐ์ค€์ž…๋‹ˆ๋‹ค. ๋ฏธ๊ตญ ์ฃผ์‹ ์‹œ์„ธ์˜ ์‹ค์‹œ๊ฐ„ ๋งˆ์ง€๋ง‰ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” Nasdaq์„ ํ†ตํ•ด ๋ณด๊ณ ๋œ ๊ฑฐ๋ž˜๋งŒ ๋ฐ˜์˜๋ฉ๋‹ˆ๋‹ค. ๋‹น์ผ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” ์ตœ์†Œ 15๋ถ„ ์ง€์—ฐ๋˜๊ฑฐ๋‚˜ ๊ฑฐ๋ž˜์†Œ ์š”๊ตฌ ์‚ฌํ•ญ์— ๋”ฐ๋ผ ๋‹ค๋ฅผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
* ์ฐธ๊ณ ์ž๋ฃŒ, ๋ถ„์„ ๋ฐ ํŠธ๋ ˆ์ด๋”ฉ ์ „๋žต์€ ์ œ3์ž ์ œ๊ณต์—…์ฒด์ธ Trading Central์—์„œ ์ œ๊ณตํ•˜๋ฉฐ, ๋ถ„์„๊ฐ€์˜ ๋…๋ฆฝ์ ์ธ ํ‰๊ฐ€์™€ ํŒ๋‹จ์— ๊ธฐ๋ฐ˜ํ•œ ์‹œ๊ฐ์œผ๋กœ, ํˆฌ์ž์ž์˜ ํˆฌ์ž ๋ชฉํ‘œ์™€ ์žฌ์ • ์ƒํ™ฉ์€ ๊ณ ๋ ค๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ 
KeyAI
๎™